Cargando…
Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK
AIM: We aimed to characterize the safety profile of pembrolizumab in advanced melanoma patients at our center to better reflect ‘real-world’ data on anti-PD-1 inhibitors. MATERIALS & METHODS: At our institution, 58 ipilimumab-naive and 30 ipilimumab-treated patients with advanced melanoma who ha...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122523/ https://www.ncbi.nlm.nih.gov/pubmed/30190931 http://dx.doi.org/10.2217/mmt-2017-0028 |